July Rare Disease Roundup

🧬 Rare Disease Roundup | July 2025: 3 Headlines That Actually Matter — and Why

For 10+ Years, I Recruited Rare Disease Startups and Biotechs—Here’s What I See Now

After a decade in the trenches, recruiting for rare disease startups and mid-size hashtag#biotechs, I’ve seen what it really takes to build something that lasts—brick by brick, approval by approval.

The energy, grit, and ingenuity in this community? Unmatched.

Even now, the most meaningful BioPharma breakthroughs—and the most career-shaping moves—come from those who don’t wait for permission.

They show up before the spotlight hits.

🔬1. Vertex Pharmaceuticals: Full Speed Ahead on Gene Editing for Sickle Cell + Thalassemia

Regulatory decisions expected within a year.

Biotechs aren’t waiting — launch teams and market education are already taking shape.

If you translate science into payer, provider, and patient strategy? You’re needed now.

🫀2. Chiesi USA, Inc. Expands U.S. Commercial Force for Rare Heart Disease

Quiet field, marketing, and access expansion is underway.

First calls go to leaders who’ve delivered in rare cardio and stayed connected.

If you’ve built trust in this space, you’re already in motion.

🚀3. Rocket Pharmaceuticals: Gene Therapy Momentum

FDA greenlight for a rare heart trial = early market planning in play.

If you’ve helped early science become sustainable strategy, you’re on the radar before roles are public.

The truth: The best roles in rare disease aren’t posted. They’re passed hand to hand—through networks built on delivery, visibility, and trust.

The intel list drops every Friday. Get on it before the weekend.

✅ The right move can change everything — but only if you see it first.

Get rare disease intel that matters — before the inbox fills Monday.

Visibility isn’t luck. It’s strategy.